Objective To analyze the relationship between serum Krebs Von den Lungen-6(KL-6)level and programmed death receptor-1(PD-1)associated immune pneumonia in patients with non-small cell lung cancer(NSCLC).Methods A total of 72 patients with NSCLC admitted to Luoyang Central Hospital from January 2021 to December 2022 were selected,who were treated with PD-1 inhibitor for 1 month.There were 43 males and 29 females,aged 63-75(68.54±3.83)years.Serum KL-6 level was detected before and after 1 month of treatment.The occurrence of PD-1 associated immune pneumonia was observed within 3 months after treatment,and the relationship between the occurrence of PD-1 associated immune pneumonia and serum KL-6 level before and after treatment was compared.t test,x2 test,and point two-column correlation analysis were used.Results After the patients were treated with PD-1 inhibitor,5 cases developed associated immune pneumonia,with an incidence of 6.94％.The serum KL-6 level in the occurrence group was(1 518.72±263.67)U/ml before treatment and(1 185.36±207.15)U/ml after treatment,which were higher than those in the non-occurrence group[(1 064.01±185.09)U/ml and(879.44± 112.06)U/ml],with statistically significant differences(both P＜0.05).By point two-column correlation analysis,the occurrence of PD-1 associated immune pneumonia was positively correlated with serum KL-6 level before and after treatment(r=0.524 and 0.551,both P＜0.001).Conclusion During PD-1 inhibitor therapy,the occurrence of PD-1 associated immune pneumonia is positively correlated with pre-and post-treatment serum KL-6 levels,and patients with higher serum KL-6 level before treatment are more likely to develop associated immune pneumonia after treatment.
关键词
非小细胞肺癌/涎液化糖链抗原-6/PD-1抑制剂/免疫性肺炎
Key words
Non-small cell lung cancer/Krebs Von den Lungen-6/PD-1 inhibitor/Immune pneumonitis
维普
万方数据